$Sonoma Pharmaceuticals, Inc.(SNOA)$ After a reverse split last year and a name change from the failed Oculus Innovative Sciences, the company wants to reflect its new positioning as a "specialty pharmaceutical company focused on the high-margin U.S. dermatology market".The reverse split and name change reflect the company's "new direction", but the burden of proof is on management to be able to execute.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
